DK3483183T3 - Immunokonjugat omfattende humaniserede rs7-antistoffer - Google Patents

Immunokonjugat omfattende humaniserede rs7-antistoffer Download PDF

Info

Publication number
DK3483183T3
DK3483183T3 DK18211762.2T DK18211762T DK3483183T3 DK 3483183 T3 DK3483183 T3 DK 3483183T3 DK 18211762 T DK18211762 T DK 18211762T DK 3483183 T3 DK3483183 T3 DK 3483183T3
Authority
DK
Denmark
Prior art keywords
amino acid
sequences
murine
antibodies
cdr2
Prior art date
Application number
DK18211762.2T
Other languages
Danish (da)
English (en)
Inventor
Serengulam V Govindan
David M Goldenberg
Zhengxing Qu
Hans J Hansen
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Application granted granted Critical
Publication of DK3483183T3 publication Critical patent/DK3483183T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK18211762.2T 2002-03-01 2003-03-03 Immunokonjugat omfattende humaniserede rs7-antistoffer DK3483183T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36022902P 2002-03-01 2002-03-01
EP08021299.6A EP2287201B1 (en) 2002-03-01 2003-03-03 RS7 antibodies

Publications (1)

Publication Number Publication Date
DK3483183T3 true DK3483183T3 (da) 2021-06-21

Family

ID=27788969

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18211762.2T DK3483183T3 (da) 2002-03-01 2003-03-03 Immunokonjugat omfattende humaniserede rs7-antistoffer

Country Status (18)

Country Link
US (10) US7238785B2 (cg-RX-API-DMAC7.html)
EP (3) EP3483183B1 (cg-RX-API-DMAC7.html)
JP (1) JP4354280B2 (cg-RX-API-DMAC7.html)
KR (1) KR101002443B1 (cg-RX-API-DMAC7.html)
CN (2) CN101264325B (cg-RX-API-DMAC7.html)
AT (1) ATE417067T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003209447B8 (cg-RX-API-DMAC7.html)
CA (1) CA2478047C (cg-RX-API-DMAC7.html)
CY (1) CY1124289T1 (cg-RX-API-DMAC7.html)
DE (1) DE60325184D1 (cg-RX-API-DMAC7.html)
DK (1) DK3483183T3 (cg-RX-API-DMAC7.html)
ES (1) ES2871905T3 (cg-RX-API-DMAC7.html)
HU (1) HUE054986T2 (cg-RX-API-DMAC7.html)
IL (1) IL163852A0 (cg-RX-API-DMAC7.html)
PT (1) PT3483183T (cg-RX-API-DMAC7.html)
SI (1) SI3483183T1 (cg-RX-API-DMAC7.html)
TR (1) TR201901824T4 (cg-RX-API-DMAC7.html)
WO (1) WO2003074566A2 (cg-RX-API-DMAC7.html)

Families Citing this family (239)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US8361464B2 (en) 2002-03-01 2013-01-29 Immunomedics, Inc. Anthracycline-Antibody Conjugates for Cancer Therapy
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US9745380B2 (en) * 2002-03-01 2017-08-29 Immunomedics, Inc. RS7 antibodies
WO2004051214A2 (en) * 2002-06-05 2004-06-17 Pharmacia & Upjohn Company Use of fluorine nmr for high throughput screening
US7993626B2 (en) * 2007-01-11 2011-08-09 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
US7597876B2 (en) * 2007-01-11 2009-10-06 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
CA2501616C (en) 2002-10-08 2015-05-12 Immunomedics, Inc. Antibody therapy
AU2003288467A1 (en) 2002-12-13 2004-07-09 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
AU2004213752B2 (en) * 2003-01-31 2008-10-23 Immunomedics, Inc. Methods and compositions for administering therapeutic and diagnostic agents
US20070128117A1 (en) * 2003-02-04 2007-06-07 Bracco International B.V. Ultrasound contrast agents and process for the preparation thereof
US10376711B2 (en) 2003-03-14 2019-08-13 Light Sciences Oncology Inc. Light generating guide wire for intravascular use
CN2885311Y (zh) 2006-01-18 2007-04-04 郑成福 经尿道光动力疗法前列腺治疗仪
CA2531118C (en) * 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
WO2005027808A1 (en) 2003-09-12 2005-03-31 Z-Medica Corporation Calcium zeolite hemostatic agent
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
EP1680138B1 (en) * 2003-10-17 2013-07-17 Novo Nordisk A/S Combination therapy
AU2005214361B2 (en) * 2004-02-13 2011-03-24 Immunomedics, Inc. Fusion proteins containing recombinant cytotoxic RNAses
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9481878B2 (en) 2004-02-13 2016-11-01 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8551480B2 (en) 2004-02-13 2013-10-08 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
EP1853326B1 (en) 2005-02-15 2016-06-15 Virginia Commonwealth University Mineral technologies (mt) for acute hemostasis and for the treatment of acute wounds and chronic ulcers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9326995B2 (en) 2005-04-04 2016-05-03 The Regents Of The University Of California Oxides for wound healing and body repair
US9243062B2 (en) * 2005-08-11 2016-01-26 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmune disease
EP1976991A1 (en) * 2006-01-24 2008-10-08 Domantis Limited Fusion proteins that contain natural junctions
US20080131428A1 (en) * 2006-02-24 2008-06-05 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20080305104A1 (en) * 2006-02-24 2008-12-11 Young David S F Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20080213267A1 (en) * 2006-02-24 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US7420040B2 (en) * 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US8938898B2 (en) 2006-04-27 2015-01-27 Z-Medica, Llc Devices for the identification of medical products
US7604819B2 (en) 2006-05-26 2009-10-20 Z-Medica Corporation Clay-based hemostatic agents and devices for the delivery thereof
US20100008978A1 (en) * 2008-05-09 2010-01-14 The Regents Of The University Of California Nanoparticles effective for internalization into cells
US20100009390A1 (en) * 2008-05-09 2010-01-14 The Regents Of The University Of California Mutant antibodies with high affinity for egfr
US7993640B2 (en) 2008-08-06 2011-08-09 Light Sciences Oncology, Inc. Enhancement of light activated therapy by immune augmentation using anti-CTLA-4 antibody
WO2010042562A2 (en) 2008-10-06 2010-04-15 Minerva Biotechnologies Corporation Muc1* antibodies
EP2386062B1 (en) * 2009-01-09 2016-01-06 Oxford Biomedica (UK) Ltd Factors
US8715662B2 (en) 2009-02-05 2014-05-06 Oncoxx Biotech S.R.L. Anti-trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors
CA2749501C (en) 2009-02-13 2017-01-10 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
DK2406284T5 (en) 2009-03-10 2017-06-12 Biogen Ma Inc ANTI-BCMA ANTIBODIES
US9296785B2 (en) 2009-04-17 2016-03-29 Wake Forest University Health Sciences IL-13 receptor binding peptides
NZ597512A (en) * 2009-07-16 2014-03-28 Beckman Coulter Inc Novel fluorescent dyes and uses thereof
EP2473187A4 (en) * 2009-08-31 2015-09-16 Immunomedics Inc COMPOSITIONS AND METHODS FOR USE OF IMMUNOXINS WITH RANPIRNASE (RAP) WITH HIGH CYTOTOXIC ACTIVITY
EP2478110B1 (en) 2009-09-16 2016-01-06 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
CA2782194C (en) * 2009-12-02 2018-01-16 Immunomedics, Inc. Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
US8663950B2 (en) 2010-01-11 2014-03-04 Arizona Board Of Regents Production of a monoclonal antibody therapeutic against west nile virus in plants
US8362207B2 (en) 2010-04-16 2013-01-29 Wake Forest University Health Sciences Multi-level specific targeting of cancer cells with IL-13
PH12012502231A1 (en) * 2010-05-17 2013-02-04 Livtech Inc Anti-human trop-2 antibody having antitumor activity in vivo
WO2011155579A1 (ja) * 2010-06-10 2011-12-15 北海道公立大学法人札幌医科大学 抗Ｔｒｏｐ－２抗体
KR101910760B1 (ko) 2010-08-23 2018-10-22 엑스바이오테크, 인크. 종양성 질병들에 대한 치료
US8858969B2 (en) 2010-09-22 2014-10-14 Z-Medica, Llc Hemostatic compositions, devices, and methods
PL2697369T3 (pl) 2011-03-25 2018-12-31 F.Hoffmann-La Roche Ag Nowe sposoby oczyszczania białek
EP2704751B1 (en) 2011-05-02 2019-04-17 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
WO2013006244A1 (en) * 2011-06-08 2013-01-10 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Bispecific monoclonal antibody therapeutics against west nile virus with improved cns penetration
EP2718321A4 (en) 2011-06-10 2015-01-28 Canada Minister Nat Defence ANTI-RICIN ANTIBODIES AND ITS USES
CN104053672A (zh) 2011-11-11 2014-09-17 瑞纳神经科学公司 Trop-2特异性抗体及其用途
US9427464B2 (en) * 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
ES2690826T3 (es) 2012-06-22 2018-11-22 Z-Medica, Llc Dispositivos hemostáticos
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014028560A2 (en) * 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US20150231241A1 (en) * 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014031584A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of aripiprazole and their use in immunoassays
JP6389176B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． アリピプラゾールハプテンに対する抗体及びその使用
CN108517014A (zh) 2012-08-21 2018-09-11 詹森药业有限公司 利培酮半抗原的抗体及其用途
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
CN104755494B (zh) 2012-10-11 2018-09-07 第一三共株式会社 抗体－药物偶联物
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US12310958B2 (en) 2012-12-13 2025-05-27 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
CA2884313C (en) 2012-12-13 2023-01-03 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US20240139324A1 (en) 2012-12-13 2024-05-02 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
WO2014124227A1 (en) 2013-02-07 2014-08-14 Immunomedics, Inc. Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
EP2774930A1 (en) 2013-03-07 2014-09-10 Aptenia S.R.L. Metallocene compounds and labeled molecules comprising the same for in vivo imaging.
PL2970492T3 (pl) 2013-03-15 2019-10-31 Univ Wake Forest Health Sciences Przeciwciała przeciwko ludzkim i psim il-13ra2
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
WO2015047510A1 (en) * 2013-09-27 2015-04-02 Immunomedics, Inc. Anti-trop-2 antibody-drug conjugates and uses thereof
GEP20237497B (en) 2013-10-18 2023-04-10 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
PL3068797T3 (pl) 2013-11-11 2020-06-29 Wake Forest University Health Sciences Konstrukty wielowalentnego celowania w nowotwory
HRP20190056T1 (hr) * 2013-12-25 2019-02-22 Daiichi Sankyo Company, Limited Konjugat anti-trop2 antitijelo-lijek
US10982221B2 (en) 2014-01-27 2021-04-20 Arizona Board Of Regents On Behalf Of Arizona State University Plant-derived antibodies and derivatives that reduce risk of antibody-dependent enhancement (ADE) of infection
CN106132436B (zh) * 2014-02-21 2021-06-15 Ibc药品公司 通过诱导对trop-2表达细胞的免疫应答的疾病疗法
EP3110445A4 (en) 2014-02-25 2017-09-27 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
CN106459213B (zh) 2014-04-03 2020-12-01 Igm生物科学股份有限公司 修饰的j链
CN112851822A (zh) * 2014-04-09 2021-05-28 广州复能基因有限公司 一种人重组乙型干扰素融合蛋白
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
US10442863B2 (en) 2014-09-08 2019-10-15 Lutana Gmbh Construct for the delivery of a molecule into the cytoplasm of a cell
JP6678941B2 (ja) 2014-10-07 2020-04-15 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 抗体−薬物コンジュゲートのネオアジュバント使用
EP3227340B1 (en) * 2014-12-04 2020-06-17 Mediterranea Theranostic S.R.L. Humanized anti-trop-2 monoclonal antibodies and uses thereof
WO2016130726A1 (en) 2015-02-10 2016-08-18 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
BR112017022666A8 (pt) 2015-04-20 2022-10-18 Tolero Pharmaceuticals Inc Preparando resposta à alvocidib por perfilamento mitocondrial
WO2016172427A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
TR201911032T4 (tr) 2015-05-18 2019-08-21 Tolero Pharmaceuticals Inc Artırılmış biyoyararlanıma sahip alvocıdıb ön ilaçları.
US20160361360A1 (en) * 2015-06-12 2016-12-15 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
SI3313443T1 (sl) 2015-06-25 2023-11-30 Immunomedics, Inc. Kombiniranje protiteles proti HLA-DR ali proti TROP-2 z zaviralci mikrotubulov, zaviralci PARP, zaviralci brutonove kinaze ali zaviralci fosfoinozitid 3-kinaze pomembno izboljša izid zdravljenja pri raku
US11173213B2 (en) 2015-06-29 2021-11-16 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
EP3316885B1 (en) 2015-07-01 2021-06-23 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
JP7083497B2 (ja) 2015-08-03 2022-06-13 スミトモ ファーマ オンコロジー， インコーポレイテッド がんの処置のための併用療法
WO2017059380A1 (en) 2015-09-30 2017-04-06 Igm Biosciences, Inc. Binding molecules with modified j-chain
JP7058213B2 (ja) 2015-09-30 2022-04-21 アイジーエム バイオサイエンシズ インコーポレイテッド 改変ｊ鎖を有する結合分子
WO2017111076A1 (ja) * 2015-12-24 2017-06-29 協和発酵キリン株式会社 α、β不飽和アミド化合物
CN108601841A (zh) 2016-02-10 2018-09-28 免疫医疗公司 Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
EP3448260A4 (en) * 2016-04-27 2019-10-09 Immunomedics, Inc. EFFICACY OF ANTI-TROP-2 SN-38 ANTIBODY CONJUGATES FOR THE THERAPY OF REZIDIVATED / REFRACTORY TUMORS AGAINST CHECKPOINT INHIBITORS
CA3029902A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
CN108697809A (zh) * 2016-08-23 2018-10-23 四川科伦博泰生物医药股份有限公司 一种抗体-药物偶联物及其制备方法和应用
JP6786973B2 (ja) * 2016-09-08 2020-11-18 ブラザー工業株式会社 画像解析装置
AU2017336867B2 (en) 2016-09-29 2024-03-14 Beijing Hanmi Pharmaceutical Co., Ltd. Heterodimeric immunoglobulin constructs and preparation methods thereof
CN108066772B (zh) * 2016-11-14 2021-07-13 中国科学院上海药物研究所 靶向tacstd2的抗体与药物偶联体(adc)分子
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
SG10201912575RA (en) 2016-12-12 2020-02-27 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate and immune checkpoint inhibitor
CN110234659A (zh) 2016-12-19 2019-09-13 特雷罗药物股份有限公司 用于敏感性分析的分析肽和方法
BR112019012847A2 (pt) 2017-01-17 2019-12-10 Daiichi Sankyo Co Ltd anticorpo ou fragmento funcional do anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produção de um anticorpo de interesse ou de um fragmento funcional do anticorpo e para produção de um conjugado de anticorpo-fármaco, conjugado de anticorpo-fármaco, composição farmacêutica, fármaco antitumoral, e, método de tratamento de um tumor.
SG10202011219YA (en) * 2017-02-27 2020-12-30 Dragonfly Therapeutics Inc Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
CA3050332A1 (en) 2017-03-27 2018-10-04 Immunomedics, Inc. Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
WO2018192407A1 (zh) 2017-04-19 2018-10-25 四川科伦博泰生物医药股份有限公司 细胞毒素和偶联物、其用途和制备方法
CN107446050A (zh) 2017-08-11 2017-12-08 百奥泰生物科技(广州)有限公司 Trop2阳性疾病治疗的化合物及方法
US11945882B2 (en) 2017-08-31 2024-04-02 Daiichi Sankyo Company, Limited Method for producing antibody-drug conjugate
JP7248578B2 (ja) 2017-08-31 2023-03-29 第一三共株式会社 抗体－薬物コンジュゲートの新規製造方法
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
IL273471B2 (en) 2017-09-29 2023-09-01 Daiichi Sankyo Co Ltd Conjugation of an antibody with a pyrrolobenzodiazepine derivative
CN120248020B (zh) 2017-12-15 2025-10-03 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途
CN108680750A (zh) * 2017-12-29 2018-10-19 广西壮族自治区人民医院 Trop2蛋白表达量的elisa检测方法及试剂盒
WO2019148186A1 (en) * 2018-01-29 2019-08-01 Silarus Therapeutics, Inc. Antibodies binding erfe and methods of use
AU2019270459B2 (en) 2018-05-18 2025-08-28 Daiichi Sankyo Co., Ltd. Anti-MUC1 antibody-drug conjugate
KR102899298B1 (ko) 2018-07-27 2025-12-12 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 약물 부위를 인식하는 단백질
EA202190403A1 (ru) 2018-07-31 2021-05-24 Дайити Санкио Компани, Лимитед Лечение метастатической опухоли головного мозга путем введения конъюгата антитело-лекарственное средство
JP7481255B2 (ja) 2018-08-23 2024-05-10 第一三共株式会社 抗体薬物複合体の感受性マーカー
IL281695B2 (en) 2018-09-26 2025-08-01 Ascendis Pharma As Degradable hyaluronic acid hydrogels
EP3876998A1 (en) 2018-11-05 2021-09-15 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing trop-2
KR20210099066A (ko) 2018-12-04 2021-08-11 스미토모 다이니폰 파마 온콜로지, 인크. 암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체
WO2020142659A2 (en) * 2019-01-04 2020-07-09 Trio Pharmaceuticals, Inc. Multi-specific protein molecules and uses thereof
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
TWI856078B (zh) 2019-03-25 2024-09-21 日商第一三共股份有限公司 抗體–吡咯并苯二氮呯衍生物結合物、其製造方法及其用途
TWI841715B (zh) 2019-03-27 2024-05-11 日商第一三共股份有限公司 抗體-吡咯并苯二氮呯衍生物結合物及ｐａｒｐ抑制劑之組合及其用途
CN113939318A (zh) 2019-05-29 2022-01-14 第一三共株式会社 抗体-药物缀合物的制剂
AU2020394204A1 (en) 2019-11-27 2022-06-02 ALX Oncology Inc. Combination therapies for treating cancer
CN115175917A (zh) * 2019-12-31 2022-10-11 启德医药科技（苏州）有限公司 药物缀合物及其应用
CN114845739B (zh) 2020-01-22 2024-07-16 上海森辉医药有限公司 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
CN118873679A (zh) 2020-01-22 2024-11-01 江苏恒瑞医药股份有限公司 抗trop-2抗体-依喜替康类似物偶联物及其医药用途
KR20230015888A (ko) 2020-03-20 2023-01-31 이뮤노메딕스, 인코오포레이티드 사시투주맙 고비테칸 요법에 대한 바이오마커
EP4146283A1 (en) 2020-05-03 2023-03-15 Levena (Suzhou) Biopharma Co., Ltd. Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same
CN115996756A (zh) 2020-05-08 2023-04-21 博尔特生物治疗药物有限公司 弹性蛋白酶底物肽连接子免疫缀合物及其用途
WO2021259162A1 (zh) * 2020-06-22 2021-12-30 四川百利药业有限责任公司 一种抗trop2抗体
EP4178624A2 (en) 2020-07-07 2023-05-17 Bionecure Therapeutics, Inc. Maytansinoids as adc payloads and their use for the treatment of cancer
US20230181471A1 (en) 2020-07-09 2023-06-15 Hoffmann-La Roche Inc. Concentrated compositions of proteins, their preparation and use thereof
IL300316A (en) 2020-08-13 2023-04-01 Bolt Biotherapeutics Inc Immune conjugates of pyrazolozapines and their uses
EP4200337A4 (en) * 2020-08-24 2024-10-02 Janux Therapeutics, Inc. ANTIBODIES TARGETING TROP2 AND CD3, AND THEIR USES
WO2022078424A1 (zh) * 2020-10-14 2022-04-21 上海翰森生物医药科技有限公司 抗trop-2抗体、其抗原结合片段或其突变体、及其医药用途
WO2022098905A2 (en) 2020-11-04 2022-05-12 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
CN116916940A (zh) * 2020-11-04 2023-10-20 美洛德生物医药公司 工程化嵌合融合蛋白组合物及其使用方法
IT202000031838A1 (it) 2020-12-22 2022-06-22 Saverio Alberti Piattaforma per ottenere anticorpi monoclonali diretti contro antigeni processati tumore-specifici
CN114685669A (zh) * 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 结合trop2的抗体及其用途
EP4196590A4 (en) 2021-01-28 2023-12-06 Genequantum Healthcare (Suzhou) Co., Ltd. LIGASE FUSION PROTEINS AND APPLICATIONS THEREOF
CN117769439A (zh) 2021-03-26 2024-03-26 博尔特生物治疗药物有限公司 2-氨基-4-甲酰胺-苯并氮杂卓免疫缀合物及其用途
CA3212907A1 (en) 2021-03-26 2022-09-29 Gary Brandt 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
TW202308701A (zh) 2021-04-29 2023-03-01 大陸商上海匯連生物醫藥有限公司 抗體偶聯藥物的製備方法及應用
US20250073349A1 (en) 2021-05-10 2025-03-06 Kawasaki Institute Of Industrial Promotion Antibody having reduced binding affinity for antigen
IL308400A (en) 2021-05-13 2024-01-01 Alx Oncology Inc Combined therapies for cancer treatment
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
JP2024520674A (ja) 2021-06-02 2024-05-24 バイオ－テラ ソリュ－ションズ，エルティーディー． 薬物コンジュゲート及びその使用
KR20240019283A (ko) 2021-06-11 2024-02-14 길리애드 사이언시즈, 인코포레이티드 Mcl-1 저해제와 항암제의 병용
CA3222752A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
EP4355785A1 (en) 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
EP4366747A4 (en) * 2021-07-09 2025-11-05 Univ Texas Chimeric antigen receptor for targeting drop-2 positive cancers
TW202320859A (zh) 2021-07-21 2023-06-01 大陸商江蘇恆瑞醫藥股份有限公司 一種含抗ｔｒｏｐ２抗體藥物偶聯物的醫藥組成物及其用途
CN118103407A (zh) 2021-08-12 2024-05-28 上海才致药成生物科技有限公司 一种双特异性重组蛋白及其用途
WO2023016488A1 (zh) 2021-08-13 2023-02-16 昆山新蕴达生物科技有限公司 一种基于微管抑制剂的抗体偶联药物
CN117881431A (zh) 2021-08-24 2024-04-12 昆山新蕴达生物科技有限公司 一种由可断裂连接子偶联的抗体偶联药物
AU2022375782A1 (en) 2021-10-28 2024-05-02 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
EP4422756A1 (en) 2021-10-29 2024-09-04 Gilead Sciences, Inc. Cd73 compounds
JP2024539993A (ja) 2021-10-29 2024-10-31 ボルト バイオセラピューティクス、インコーポレーテッド システイン変異抗体を含むｔｌｒアゴニスト免疫複合体、及びその使用
WO2023100829A1 (ja) 2021-11-30 2023-06-08 第一三共株式会社 プロテアーゼ分解性マスク抗体
CN116199784A (zh) * 2021-11-30 2023-06-02 泽达生物医药有限公司 抗trop-2/pd-l1双特异性抗体
JP2024545138A (ja) 2021-12-09 2024-12-05 クンシャン シンユンター バイオテック カンパニー，リミティド 親和性が改善された抗体薬物複合体、その調製法、及びその応用
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
KR20240123836A (ko) 2021-12-22 2024-08-14 길리애드 사이언시즈, 인코포레이티드 이카로스 아연 핑거 패밀리 분해제 및 이의 용도
US20250049940A1 (en) 2022-01-13 2025-02-13 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Combined Use of Anti-TROP-2 Antibody-drug Conjugate and other Therapeutic Agents
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023153442A1 (ja) 2022-02-09 2023-08-17 第一三共株式会社 環境応答性マスク抗体及びその利用
EP4480499A1 (en) 2022-02-16 2024-12-25 Medilink Therapeutics (Suzhou) Co., Ltd. Conjugate of antibody-eribulin or derivative thereof, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and use thereof
CA3252619A1 (en) 2022-02-23 2023-08-31 Xencor, Inc. Anti-CD28 and anti-PSMA antibodies
US20240059786A1 (en) * 2022-02-24 2024-02-22 Xencor, Inc. Anti-cd28 x anti-trop2 antibodies
ES2999273T3 (en) 2022-03-17 2025-02-25 Gilead Sciences Inc Ikaros zinc finger family degraders and uses thereof
WO2023180485A1 (en) 2022-03-23 2023-09-28 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing trop-2
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
EP4508083A1 (en) 2022-04-13 2025-02-19 Gilead Sciences, Inc. Combination therapy for treating tumor antigen expressing cancers
CA3256033A1 (en) 2022-04-13 2023-10-19 Arcus Biosciences, Inc. POLYTHERAPY FOR THE TREATMENT OF CANCERS EXPRESSING TOO MUCH-2
CN119487038A (zh) 2022-04-21 2025-02-18 吉利德科学公司 Kras g12d调节化合物
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. CHELETARIANS AND BIFUNCTIONAL CONJUGATES
CN119421724A (zh) 2022-06-27 2025-02-11 百奥泰生物制药股份有限公司 治疗实体瘤的方法
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
CN117801107A (zh) 2022-09-30 2024-04-02 上海迪诺医药科技有限公司 苯并氮杂卓衍生物、含其的偶联物及其应用
WO2024097812A1 (en) 2022-11-04 2024-05-10 Gilead Sciences, Inc. Therapy for treating bladder cancer
EP4623937A1 (en) 2022-11-25 2025-10-01 Minghui Pharmaceutical (Hangzhou) Limited Anti-tumor compound and use thereof
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
EP4637833A2 (en) 2022-12-23 2025-10-29 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
AU2024210908A1 (en) 2023-01-18 2025-08-21 Tyligand Bioscience (Shanghai) Limited Antibody-drug conjugate and use thereof
WO2024173387A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof
US20240383922A1 (en) 2023-04-11 2024-11-21 Gilead Sciences, Inc. KRAS Modulating Compounds
AU2024255999A1 (en) * 2023-04-14 2025-10-16 Xencor, Inc. Anti-cd28 x anti-trop2 antibodies
CN121263210A (zh) 2023-04-17 2026-01-02 沛科生物公司 抗体和抗体-药物偶联物以及使用方法和合成工艺及中间体
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024226388A1 (en) * 2023-04-24 2024-10-31 Merck Sharp & Dohme Llc Anti-trop2 antibody-drug conjugates comprising pnu-159682 derivatives
TW202506193A (zh) 2023-04-24 2025-02-16 美商默沙東有限責任公司 Trop2結合劑及其結合物
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
WO2025019790A1 (en) 2023-07-19 2025-01-23 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
TW202519517A (zh) 2023-07-26 2025-05-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2025038770A1 (en) 2023-08-15 2025-02-20 Gilead Sciences, Inc. Treatment of non-small cell lung cancer using sacituzumab govitecan and an anti-pd-1 antibody or antigen binding fragment thereof
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250135019A1 (en) 2023-10-13 2025-05-01 Gilead Sciences, Inc. Combination therapies for treating cancers
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
EP4552657A1 (en) 2023-11-07 2025-05-14 Bayer Aktiengesellschaft Radiopharmaceutical complexes and combinations
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025149014A1 (en) 2024-01-12 2025-07-17 Genequantum Healthcare (Suzhou) Co., Ltd. Pharmaceutical composition
CN120659813A (zh) * 2024-01-15 2025-09-16 石药集团巨石生物制药有限公司 结合trop2的抗体或抗体片段及包含其的药物偶联物
WO2025153092A1 (en) * 2024-01-18 2025-07-24 Beijing Joinn Biologics Co., Ltd Antibody-drug conjugate
WO2025159982A1 (en) 2024-01-22 2025-07-31 Gilead Sciences, Inc. Treatment of non-small cell lung cancer using sacituzumab govitecan
WO2025212469A1 (en) * 2024-04-03 2025-10-09 Merck Sharp & Dohme Llc Use of an immunoconjugate for the treatment of gastric cancer
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025251025A1 (en) 2024-05-31 2025-12-04 Gilead Sciences, Inc. Sacituzumab govitecan formulations and methods of manufacture

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4624846A (en) 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
FR2604092B1 (fr) 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5734033A (en) 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5185254A (en) * 1988-12-29 1993-02-09 The Wistar Institute Gene family of tumor-associated antigens
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP1550729B1 (en) 1992-09-25 2009-05-27 Avipep Pty Limited Target binding polypeptide comprising an IG-like VL domain linked to an IG-like VH domain
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
GB9316989D0 (en) * 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
ATE306930T1 (de) 1994-08-12 2005-11-15 Immunomedics Inc Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
IL122614A0 (en) 1995-06-15 1998-08-16 Introgene Bv Packaging systems for human recombinant adenovirus to be used in gene therapy
JP2001501801A (ja) 1995-10-19 2001-02-13 ブリストル−マイヤーズ スクイッブ カンパニー モノクローナル抗体ｂｒ１１０およびその使用
DE69729283T2 (de) 1996-03-20 2005-05-25 Immunomedics, Inc. GLYKOSYLIERTE IgG ANTIKÖRPER
DE69737867T2 (de) 1996-05-03 2007-10-18 Immunomedics, Inc. Zielgerichtete kombinations-immuntherapie für krebs
US6558669B1 (en) * 1996-08-28 2003-05-06 Immunomedics, Inc. Stable radioiodine conjugates and methods for their synthesis
WO1998012227A1 (en) * 1996-09-19 1998-03-26 Diagnocure Inc. Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
US6653104B2 (en) * 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
DE69942148D1 (de) * 1998-06-22 2010-04-29 Immunomedics Inc Gebrauch von bispezifischen antikörpern in diagnose und therapie
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
ATE296839T1 (de) * 1999-03-01 2005-06-15 Genentech Inc Antikörper zur krebsbehandlung und -diagnose
GB9911569D0 (en) * 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
US6824780B1 (en) 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
DE10034607A1 (de) * 2000-07-20 2002-02-07 Gundram Jung Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren
PL372144A1 (en) * 2001-12-26 2005-07-11 Immunomedics, Inc. Methods of generating multispecific, multivalent agents from v sb h /sb and v sb l /sb domains
US9770517B2 (en) * 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20080213267A1 (en) 2006-02-24 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US7420040B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20080305104A1 (en) 2006-02-24 2008-12-11 Young David S F Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US8715662B2 (en) 2009-02-05 2014-05-06 Oncoxx Biotech S.R.L. Anti-trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors
PH12012502231A1 (en) 2010-05-17 2013-02-04 Livtech Inc Anti-human trop-2 antibody having antitumor activity in vivo
WO2011155579A1 (ja) 2010-06-10 2011-12-15 北海道公立大学法人札幌医科大学 抗Ｔｒｏｐ－２抗体
EP2694111B1 (en) 2011-04-01 2016-08-10 Wyeth LLC Antibody-drug conjugates
CN104053672A (zh) 2011-11-11 2014-09-17 瑞纳神经科学公司 Trop-2特异性抗体及其用途
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
KR102188537B1 (ko) 2019-08-14 2020-12-08 라인플러스 주식회사 유니캐스트 및 멀티캐스트를 이용한 그룹 통화 방법 및 시스템

Also Published As

Publication number Publication date
CN101264325B (zh) 2017-03-01
WO2003074566A2 (en) 2003-09-12
US20140120035A1 (en) 2014-05-01
AU2003209447B8 (en) 2008-10-23
US9849176B2 (en) 2017-12-26
CN101264325A (zh) 2008-09-17
EP3483183B1 (en) 2021-04-21
TR201901824T4 (tr) 2019-03-21
SI3483183T1 (sl) 2021-08-31
KR20040089694A (ko) 2004-10-21
US10179171B2 (en) 2019-01-15
US8084583B2 (en) 2011-12-27
ATE417067T1 (de) 2008-12-15
DE60325184D1 (de) 2009-01-22
US8758752B2 (en) 2014-06-24
EP2287201A2 (en) 2011-02-23
US9833511B2 (en) 2017-12-05
EP1483295A2 (en) 2004-12-08
US20040001825A1 (en) 2004-01-01
US20170274079A1 (en) 2017-09-28
CA2478047C (en) 2014-01-21
EP1483295B1 (en) 2008-12-10
US9999668B2 (en) 2018-06-19
US20180133322A1 (en) 2018-05-17
CN1649903A (zh) 2005-08-03
EP2287201B1 (en) 2018-12-12
US20120141372A1 (en) 2012-06-07
US20100221177A1 (en) 2010-09-02
PT3483183T (pt) 2021-06-02
KR101002443B1 (ko) 2010-12-17
HUE054986T2 (hu) 2021-10-28
JP4354280B2 (ja) 2009-10-28
WO2003074566A3 (en) 2004-03-04
US20190083621A1 (en) 2019-03-21
US20180250406A1 (en) 2018-09-06
EP3483183A1 (en) 2019-05-15
EP2287201A3 (en) 2012-04-04
CN100360567C (zh) 2008-01-09
AU2003209447B2 (en) 2008-09-18
US7517964B2 (en) 2009-04-14
JP2006502698A (ja) 2006-01-26
CA2478047A1 (en) 2003-09-12
US8574575B2 (en) 2013-11-05
US20070212350A1 (en) 2007-09-13
AU2003209447A1 (en) 2003-09-16
IL163852A0 (en) 2005-12-18
CY1124289T1 (el) 2022-07-22
ES2871905T3 (es) 2021-11-02
US20140286861A1 (en) 2014-09-25
US7238785B2 (en) 2007-07-03

Similar Documents

Publication Publication Date Title
CY1124289T1 (el) Ανοσοσυζευμα που περιλαμβανει εξανθρωποποιημενα αντισωματα rs7
HRP20020693B1 (hr) HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID Aß
HRP20181069T1 (hr) Antagonistička protutijela na il-17
AR035581A1 (es) Anticuerpos para il-1beta humana
NZ593068A (en) IL-18 antibody
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
NZ599196A (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
CY1113296T1 (el) Υβριδικο ανθρωπινο/τρωκτικου ιgg αντισωμα προς cd3 και μεθοδοι κατασκευης αυτου
GEP20074222B (en) Antibodies to cd40
TW200716182A (en) Antibodies directed to CD20 and uses thereof
EP2796466A3 (en) Humanized antibody molecules specific for IL-31
SG155883A1 (en) Anti-cd3 antibodies and methods of use thereof
BR0207151A (pt) Moléculas de aglutinação terapêuticas
BR0318454A (pt) anticorpos dirigidos a hormÈnio da paratireóide (pth) e seus usos
PE20030104A1 (es) Anticuerpos humanos para cd154
BR0112086A (pt) Anticorpos para mcp-1 humano
EA200100698A1 (ru) Моноклональные антитела человека к ctla-4
SG151284A1 (en) Antibodies against ccr5 and uses thereof
NZ594275A (en) B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
WO2003057857A3 (en) Antibodies directed to pdgfd and uses thereof
ATE476994T1 (de) Antikörper gegen gpnmb und ihre verwendungen
WO2005112564A3 (en) Germline and sequence variants of humanized antibodies and methods of making and using them
ECSP066432A (es) Moléculas de enlace terapéuticas
WO2004050032A3 (en) Antibodies against drugs of abuse
WO2007065037A3 (en) Antibodies against mmp-13 (collagenase-3) and uses thereof